Truist Financial Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $43.00

Keros Therapeutics (NASDAQ:KROS) had its price objective cut by Truist Financial from $100.00 to $43.00 in a research report report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. Scotiabank dropped their target price on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a report on Friday, December 13th. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Oppenheimer decreased their target price on shares of Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, December 16th. Finally, HC Wainwright dropped their price target on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $75.00.

Keros Therapeutics Trading Down 2.4 %

Shares of Keros Therapeutics stock opened at $16.71 on Monday. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00. The firm’s 50-day moving average price is $53.23 and its 200 day moving average price is $51.17. The firm has a market capitalization of $676.87 million, a PE ratio of -3.21 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same quarter in the previous year, the business posted ($1.33) EPS. Keros Therapeutics’s quarterly revenue was up 4750.0% on a year-over-year basis. On average, sell-side analysts predict that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. KBC Group NV grew its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new position in Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics during the second quarter valued at about $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics during the third quarter valued at about $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.